Clinical trialsCompany release

Lipocine doses first patient in second Phase 3 trial of oral brexanolone for postpartum depression

🇺🇸 Lipocine Inc. (LPCN) · Tue 10 Nov 2026

Lipocine has begun the BLOOM study of LPCN 1154, a 48-hour at-home oral brexanolone regimen, after an earlier Phase 3 trial missed its primary endpoint.

Lipocine announced on 10 November 2026 that the first participant has been dosed in BLOOM, a placebo-controlled Phase 3 outpatient study of LPCN 1154 in postpartum depression. The product is an oral formulation of brexanolone given as a 48-hour regimen that patients can take at home.

The company plans to enrol about 120 participants. Topline results are expected in the second half of 2027.

BLOOM follows an earlier Phase 3 trial of LPCN 1154 that did not meet its primary endpoint. Lipocine says the new study's design incorporates feedback from the US Food and Drug Administration.

According to the company, the agency's feedback indicated that one positive, well-controlled Phase 3 trial is still needed to support a 505(b)(2) new drug application. This is a US route that allows a sponsor to rely in part on data the applicant did not generate itself, such as previously established findings for an approved drug.

What it means for your team

  • Regulatory teams tracking postpartum depression should note that Lipocine reports a single positive, well-controlled Phase 3 trial is still needed for a 505(b)(2) filing, per FDA feedback described by the company.
  • Market-access teams should treat any outpatient, at-home oral option as a development-stage prospect only; topline data are not expected until the second half of 2027.
  • The earlier Phase 3 trial missed its primary endpoint, so BLOOM's outcome will determine whether the filing path described by Lipocine remains viable.

Company's press release (SEC filing): Lipocine Inc. ↗

Article written by VigiEye from the official source (Lipocine Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →